With research and innovation consistently serving as the spearhead for the Tsetis Pharmaceutical Group (OFET), InterMed recently secured a new European Patent for the dietary supplement Olivomed; notably, this patent has already been registered outside Europe as well.
InterMed secures European patent for Olivomed supplement
The Olivomed dietary supplement contains olive fruit extract rich in polyphenols and contributes, based on clinical study results, to reducing body mass index (BMI) and visceral fat in overweight individuals. Additionally, the contained olive oil polyphenols help protect blood lipids from oxidative stress. Strong evidence that innovation constitutes a strategic priority for OFET is the fact that the group has historically secured over 100 patents in more than 60 countries. Today, 89 are active (73 national and 16 European), 39 are under examination (24 national applications and 15 European), while 34 of its formulations are under protection.
With a vision to strengthen the new generation of scientists and researchers as well as curb scientific migration, since 2017 the President and CEO of OFET Julia Tsetis, together with her sister Irene, founded the Non-Profit Civil Company KLEON TSETIS in memory of their father, a researcher pharmacist and founder of the Group. Through the KLEON TSETIS non-profit organization to date, 46 scholarships have been awarded to outstanding students of health sciences.
